Top Page
Nanobiotix
(NASDAQ:NBTX)
Nanobiotix (NBTX) vs. SPDR S&P 500 ETF (SPY)
Nanobiotix Business Overview & Revenue Model
Nanobiotix Earnings Call Summary
Nanobiotix Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.74M | -11.61M | 36.21M | 4.78M | 2.65M | 50.00K |
| Gross Profit | 5.74M | -11.61M | 36.21M | 3.79M | 2.65M | 50.00K |
| EBITDA | -33.99M | -58.32M | -23.69M | -44.22M | -45.60M | -31.49M |
| Net Income | -51.64M | -68.13M | -39.70M | -57.04M | -47.00M | -33.62M |
Balance Sheet | ||||||
| Total Assets | 45.17M | 67.42M | 93.90M | 59.77M | 101.77M | 134.03M |
| Cash, Cash Equivalents and Short-Term Investments | 28.82M | 49.74M | 75.28M | 41.39M | 83.92M | 119.15M |
| Total Debt | 51.24M | 50.90M | 50.56M | 53.17M | 46.02M | 48.98M |
| Total Liabilities | 114.13M | 133.12M | 95.74M | 86.81M | 74.98M | 63.56M |
| Stockholders Equity | -68.95M | -65.70M | -1.84M | -27.05M | 26.79M | 70.47M |
Cash Flow | ||||||
| Free Cash Flow | -31.64M | -20.40M | -12.81M | -37.20M | -30.11M | -27.64M |
| Operating Cash Flow | -31.13M | -19.55M | -12.48M | -37.10M | -29.87M | -27.54M |
| Investing Cash Flow | -617.00K | -955.00K | -349.00K | 138.00K | -242.00K | -112.00K |
| Financing Cash Flow | -5.31M | -5.13M | 46.77M | -5.65M | -5.18M | 111.77M |
Nanobiotix Technical Analysis
Nanobiotix Risk Analysis
Nanobiotix Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.48B | -7.62 | -85.59% | ― | ― | 0.69% | |
56 Neutral | $987.17M | -8.08 | -26.64% | ― | ― | -103.95% | |
54 Neutral | $1.20B | -17.70 | -22.38% | ― | 2147.20% | -269.99% | |
52 Neutral | $1.75B | -14.14 | -40.80% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.03B | ― | ― | ― | ― | ― | |
47 Neutral | $1.21B | -4.98 | -68.33% | ― | ― | -38.04% |
Nanobiotix Corporate Events
On December 17, 2025, Nanobiotix released details regarding its share capital and voting rights as of November 30, 2025. The company reported 48,401,118 outstanding shares with 50,079,581 exercisable voting rights. This update underscores its commitment to transparency for stakeholders and compliance with regulatory standards, potentially bolstering investor confidence and affirming the company’s competitive positioning in the biotechnology industry.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On December 15, 2025, Nanobiotix announced its inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective after the market closes on December 19, 2025. This inclusion is expected to enhance the company’s visibility among institutional investors, strengthen its presence in European equity markets, and increase exposure to index-linked investment strategies, reflecting market confidence in its long-term strategy and innovative nanotherapeutic solutions.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On December 1, 2025, Nanobiotix S.A. announced the disclosure of transactions by persons discharging managerial responsibilities in compliance with EU Market Abuse Regulation. This announcement included details of a significant transaction on November 26, 2025, where shares were sold to repay bank loans used for financing stock options. This transaction allowed the company to eliminate the pledge on the remaining shares, potentially improving its financial flexibility and stakeholder confidence.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On November 24, 2025, Nanobiotix announced significant progress in its operations and financial strategy, including the closing of a non-dilutive royalty financing deal with HealthCare Royalty valued at up to $71 million. This move is expected to support the company’s long-term growth. Additionally, the company reported advancements in its JNJ-1900 (NBTXR3) clinical development program, including the transfer of the NANORAY-312 study sponsorship to Johnson & Johnson and the presentation of new data from a Phase 1 esophageal cancer study. The company also highlighted progress in its Curadigm Nanoprimer program, with new patent applications and collaborations. These developments position Nanobiotix for accelerated growth in 2026, with ongoing and upcoming clinical trials expected to provide further insights into the potential of its innovative cancer treatments.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On November 13, 2025, Nanobiotix announced significant advancements in its Curadigm Nanoprimer platform, including the filing of four new patent applications to expand its intellectual property portfolio. The company presented new preclinical data at the 2025 Partnership Opportunities in Drug Delivery conference, showcasing the Nanoprimer’s potential to improve the delivery of therapeutic vaccines. These developments are expected to drive long-term growth for Nanobiotix by supporting both internal pipeline development and external collaborations, with numerous material transfer agreements already in place.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On November 14, 2025, Nanobiotix announced its updated voting rights and share capital information as of October 31, 2025. The company reported 48,237,471 shares outstanding, with 50,267,962 theoretical voting rights and 50,245,844 exercisable voting rights. This announcement is significant for stakeholders as it provides transparency in shareholder voting power and aligns with regulatory requirements.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On November 11, 2025, Nanobiotix announced its participation in the Jefferies London Healthcare Conference, scheduled for November 17, 2025. The company’s CEO, Laurent Levy, and CFO, Bart van Rhijn, will engage in a fireside chat at the event, which will be webcast live. This participation underscores Nanobiotix’s commitment to engaging with the investor community and highlights its strategic positioning in the biotechnology industry.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On November 3, 2025, Nanobiotix announced its participation in several investor conferences scheduled for the week of November 10, 2025. The company’s management, including CEO Laurent Levy and CFO Bart van Rhijn, will present at the UBS Global Healthcare Conference, Guggenheim’s Annual Healthcare Innovation Conference, and the Stifel Healthcare Conference. These events are expected to enhance Nanobiotix’s visibility within the healthcare investment community and potentially attract new stakeholders.
The most recent analyst rating on (NBTX) stock is a Hold with a $20.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On October 31, 2025, Nanobiotix announced a strategic royalty monetization agreement with HealthCare Royalty, securing up to $71 million in non-dilutive funding. This agreement is expected to extend the company’s cash runway into early 2028, supporting the development of its nanotherapeutic platforms and advancing key milestones in head and neck and lung cancer treatments. The deal involves HealthCare Royalty receiving a capped portion of milestones and royalties from sales of JNJ-1900 (NBTXR3), a novel oncology product. This financing aims to establish a financial foundation for Nanobiotix’s long-term growth and self-sustainability, reflecting confidence in its innovative cancer treatment approach.
The most recent analyst rating on (NBTX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On October 24, 2025, Nanobiotix announced updates to its JNJ-1900 (NBTXR3) clinical development program, highlighting the transfer of sponsorship and operational control of the Phase 3 NANORAY-312 trial to Johnson & Johnson. This strategic move is expected to enhance the development and potential scalability of NBTXR3 across various solid tumor indications, especially in combination with radiotherapy. The interim data for the NANORAY-312 trial is anticipated to be analyzed and reported in the first half of 2027, marking a significant milestone in the company’s collaboration with J&J and its ongoing efforts to expand treatment possibilities for cancer patients.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
On October 15, 2025, Nanobiotix announced its voting rights and share capital details as of September 30, 2025. The company reported 48,237,471 outstanding shares, with 50,318,257 theoretical voting rights and 50,296,139 exercisable voting rights. This update is crucial for stakeholders to understand the company’s current shareholder structure and voting power distribution.
The most recent analyst rating on (NBTX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.